HSCS logo

HeartSciences Inc

HSCS

Build a strategy around HSCS

Accountable AI Logo

HeartSciences Inc AI Insights

Informational only. Not investment advice.
As of 2026-02-20

Snapshot

  • Cash burn of 7.5M TTM against 2.0M cash leaves ~3 months runway without financing[Free Cash Flow TTM]
  • R&D spend of 3.7M TTM is 425x revenue (8.7K) - pre-commercial stage company[Research and Development TTM]
  • Intangibles of 1.8M represent 44% of equity - IP valuation critical to thesis[Goodwill and Other Intangible Assets]

Watch Triggers

  • Cash and Equivalents: Falls below 1.0M or financing announcedSub-1M cash triggers going concern; financing terms reveal dilution severity
  • Total Revenue TTM: Exceeds 100K quarterlyAny meaningful revenue signals commercial viability and extends runway thesis
  • Accounts Receivable: Any positive balanceZero AR suggests no sales pipeline; positive AR indicates customer adoption

Bull Case

Gross margin of 58% TTM indicates viable unit economics if commercialization succeeds; 657K inventory suggests product readiness

Gross Margin TTMInventory

Debt/equity of 0.21 provides balance sheet flexibility for equity financing without covenant constraints

Debt to Equity

Bear Case

Revenue of 8.7K TTM with -5% 3Y growth signals failed commercialization; operating loss of 8.2M is 950x revenue

Total Revenue TTMOperating Income TTMTotal Revenue 3yr Growth TTM

Cash runway under 3 months with no receivables pipeline; equity raise at distressed valuation or bankruptcy likely

Cash and EquivalentsFree Cash Flow TTMAccounts Receivable

Bull vs Bear Balance

AI-generated sentiment analysis based on fundamental metrics and market conditions.

BearBull
15%

Leverage HSCS's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.

Take Me to The Editor

Forward Thesis

Survival depends on near-term financing; dilution or failure highly probable within 6 months

3-12mhigh
  • Cash of 2.0M vs monthly burn ~625K
  • Zero accounts receivable suggests no commercial traction
  • Current debt of 500K due near-term
FCF TTM: -7.5MCash: 2.0MRevenue TTM: 8.7K

Valuation Context

Caveats

Public Strategies Rankings

See how HeartSciences Inc ranks across different investment strategies.

Leverage HSCS's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.

Data Partners
Morningstar Logo

Fundamental company data provided by Morningstar, updated daily.

Accountable Finance, Inc. Disclaimer
accountable.finance is not operated by a broker or a dealer. Under no circumstances does any information posted on accountable.finance represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. In no event shall accountable.finance be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on accountable.finance, or relating to the use of, or inability to use, accountable.finance or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. Stock quotes and fundamental company data provided by Morningstar, updated daily.

Accountable Logo
© 2026 Accountable Finance, Inc. All rights reserved.